Bifemelane HCl is a novel and potent nootropic drug.

Ro 41-1049 hydrochloride, the hydrochloride salt of Ro 41-1049, is a novel, potent, selective, reversible and orally bioavailable inhibitor of MAO-A (Monoamine oxidase).

TB5 is a novel, potent, selective, reversible and competitive inhibitor of hMAO-B (human monoamine oxidase-B) with Ki value of 0.11±0.01 μM.

J147 is a potent neuroprotective and neurotrophic compound. J147 protects against neurotoxicity in cortical neurons in vitro (EC50 = 25 – 200 nM).

Phenelzine Sulfate is a novel and potent monoamine oxidase inhibitor.

Lysyl oxidase inhbitor 1 is a novel and potent inhibitor of lysyl oxidase, whose upregulation by tumor cells may promote metastasis of the existing tumor, causing it to become malignant and cancerous.

Mofegiline HCl (MDL-72,974; MDL72,974), the hydrochloride salt of Mofegiline, is a potent and irreversible inhibitor of monoamine oxidase B (MAO-B) and semicarbazide-sensitive amine oxidase (SSAO) with the potential to be used for the treatment for various diseases.

Clorgyline, formerly known as Clorgiline, M&B 9302 or MB9302, is a potent, irreversible and selective inhibitor of monoamine oxidase (MAO), it is structurally related to pargyline which is described as an antidepressant.

Iproniazid (brand/other names of Marsilid, Rivivol, Euphozid, Iprazid, Ipronid, Ipronin) is a non-selective, and irreversible monoamine oxidase inhibitor (MAOI).

Lazabemide (also known as Ro 19-6327; proposed trade names Pakio, Tempium) is novel, potent, selective, reversible monoamine oxidase B (MAO-B) inhibitor with IC50 values are 0.03 and > 100 μM for MAO-B and MAO-A respectively.